SLC12A5 and systemic lupus erythematosus: The antiepileptic role of enhanced KCC2 activity has also been suggested by Moore et al., 2018, who showed that KCC2 potentiation delayed the onset of an SLE after 4-AP application in vitro and reduced the severity of kainate-induced seizures in vivo.